Physician profile
Ryan W Lapour
NPI 1043327521
$322.19
in general payments reported to CMS, 2019-2025
9 companies · $64.45 in 2025
The $64.45 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.34 · 2020: $14.41 · 2021: $39.47 · 2022: $85.99 · 2023: $53.61 · 2024: $41.92 · 2025: $64.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $53.02 | 2020-2022 | |
| Horizon Therapeutics Plc | $50.90 | 2021-2023 | Tepezza |
| Alcon Vision LLC | $46.34 | 2023-2025 | Rocklatan, Tryptyr |
| Bausch & Lomb Americas INC. | $41.92 | 2024 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $38.63 | 2022 | |
| Abbvie INC. | $27.27 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $23.96 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.34 | 2019 | |
| Thea Pharma INC. | $17.81 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lapour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.